Clinical trial TOUCH
Phase II open-label, multicenter, randomized trial of neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer (IBCSG 55-17 / TOUCH)
Cancers | |
---|---|
Organ | Breast |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 2 |
Academic trial | Non |
Sponsor | IBCSG |
EudraCT Identifier | 2017-005067-40 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03644186 |
Inclusion criteria | ER+/HER2+. cT1-3. N0-1. >1 cm. Neoadjuvant. Age >65 years old |
Last update |